Cargando…
Basic and clinical study of efficacy and adverse effects of flumatinib in Ph(+) ALL
Objective: To investigate the efficacy and safety of chemotherapy in treating Ph+ ALL based on flumatinib. Methods: The clinical data of 29 patients with Ph+ ALL receiving flumatinib-based chemotherapy in Sichuan Provincial People’s Hospital from January 2020 to January 2023 were collected for analy...
Autores principales: | Wang, Jun, Wu, Jiafei, Wang, Yijing, Zheng, Boyue, Wang, Yu, Jiang, Chuanyan, Zou, Mengying, Li, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196016/ https://www.ncbi.nlm.nih.gov/pubmed/37214433 http://dx.doi.org/10.3389/fphar.2023.1178393 |
Ejemplares similares
-
Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
por: Liu, Ya-nan, et al.
Publicado: (2023) -
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
por: Jiang, Bo, et al.
Publicado: (2023) -
PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Y., et al.
Publicado: (2022) -
Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects
por: Kuang, Yun, et al.
Publicado: (2020) -
P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL
por: Liu, Weiyang, et al.
Publicado: (2023)